Advertisement

Pharmaceutical & Diagnostic Innovation

, Volume 1, Issue 1, pp 36–37 | Cite as

Diagnostic Developments

News and View
  • 5 Downloads

Battle of the BNP Tests

The market for brain natriuretic peptide (BNP) tests is a rapidly expanding sector of the cardiovascular testing market. In July, Roche Diagnostics and SYN X Pharma, Inc. cross-licensed nonexclusive rights relating to the development and marketing of immunoassays that detect N-terminal pro-BNP (NT-proBNP), a marker for congestive heart failure (CHF) [see p59 for details]. While both Roche and SYN X have patents relating to the NT-proBNP marker, the deal restricts SYN X to the development of point-of-care tests.

This cross-licensing agreement is an important step for SYN X as the company is planning to release its NT-proBNP point-of-care test (Nexus Dx™) in the US market by the second half of 2004 [Gray Sheet 2003; 29 (30): 6]. The Nexus Dx test will combine two cardiac biomarkers, troponin I and NT-proBNP. The first BNP test (Triage® BNP) was launched in the US by Biosite Incorporatedin November 2000. Two years later, the US FDA approved Roche’s Elecsys proBNP...

Copyright information

© Adis Data Information BV 2003

Personalised recommendations